Furthermore, besides immunotherapy, targeted therapies (including VEGF/VEGFR inhibitors and mTOR inhibitors) may have immunomodulatory effects on ccRCC and may remodel the TIME. Here, MTOR is linked to nonpapillary renal cell carcinoma.